Lipids & metabolic liver disease
Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial
Authors' conclusion
Six-month treatment with high-dose coenzyme-Q10 reduces liver steatosis and improves endothelial, vascular and left ventricle myocardial function in patients with MASLD, demonstrating significant improvements in micro- and macro-vasculature function.
Study context
- Population
- Patients with MASLD
- Participants
- 60 patients
- Comparison
- Coenzyme Q10 240 mg daily vs placebo
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Endothelial, vascular and myocardial function and liver steatosis in the coenzyme-Q10 group: 6 months vs baseline
- Perfused boundary region, 6 months vs baseline (coenzyme-Q10)
- 2.18 ± 0.23 vs 2.29 ± 0.18 μm
- Pulse-wave velocity, 6 months vs baseline (coenzyme-Q10)
- 9.5 ± 2 vs 10.2 ± 2.3 m/s
- Controlled attenuation parameter, 6 months vs baseline (coenzyme-Q10)
- 280.9 ± 33.4 vs 304.8 ± 37.4 dB/m
- Flow-mediated dilation, 6 months vs baseline (coenzyme-Q10)
- 6.1 ± 3.8 vs 4.3 ± 2.8%
- Global longitudinal strain, 6 months vs baseline (coenzyme-Q10)
- −19.6 ± 1.6 vs −18.8 ± 1.9%
- Coronary flow reserve, 6 months vs baseline (coenzyme-Q10)
- 3.1 ± 0.4 vs 2.8 ± 0.4
- All changes vs baseline (coenzyme-Q10)
- p < 0.05
- Placebo: no improvement during 6-month follow-up
- p > 0.05
Further findings
Correlations in coenzyme-Q10 group · 6 months
- Reduction in controlled attenuation parameter positively related to reduction in perfused boundary region and pulse-wave velocity, and inversely related to increase in coronary flow reserve and flow-mediated dilation
- P < 0.05 for all relations
Original publication
Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial. Cardiovasc Diabetol. Published 10 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →